Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Interplay between exercise and dietary fat modulates myelinogenesis in the central nervous system.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Astrocyte-derived lactosylceramide implicated in multiple sclerosis.
Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Interferon in relapsing-remitting multiple sclerosis.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.
Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM)
Antioxidant properties of the triaminopyridine, flupirtine.
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
A G protein-coupled receptor is essential for Schwann cells to initiate myelination.
Gpr126 is essential for peripheral nerve development and myelination in mammals.
The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients.
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
Receptos doses first patient in Phase 2/3 trial for RPC1063 in multiple sclerosis
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
Long term safety and efficacy study of teriflunomide 7 mg or 14 mg in patients with relapsing-remitting multiple sclerosis
Repurposing drugs for disease modification in multiple sclerosis

Pages